{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:54:48Z","timestamp":1790963688102,"version":"4.1.0"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004955","name":"\u00d6sterreichische Forschungsf\u00f6rderungsgesellschaft","doi-asserted-by":"publisher","award":["852068"],"award-info":[{"award-number":["852068"]}],"id":[{"id":"10.13039\/501100004955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>VISTA (PD-1H) is an immune regulatory molecule considered part of the next wave of immuno-oncology targets. VISTA is an immunoglobulin (Ig) superfamily cell surface molecule mainly expressed on myeloid cells, and to some extent on NK cells and T cells. In previous preclinical studies, some VISTA-targeting antibodies provided immune inhibitory signals, while other antibodies triggered immune stimulatory signals. Importantly, for therapeutic antibodies, the isotype backbone can have a strong impact on antibody function. To elucidate the mode of action of immune stimulatory anti-VISTA antibodies, we studied three different anti-human VISTA antibody clones, each on three different IgG isotypes currently used for therapeutic antibodies: unaltered IgG1 (IgG1-WT), IgG1-KO (IgG1-LL234,235AA-variant with reduced Fc-effector function), and IgG4-Pro (IgG4- S228P-variant with stabilized hinge region). Antibody functionality was analysed in mixed leukocyte reaction (MLR) of human peripheral blood mononuclear cells (PBMCs), as a model system for ongoing immune reactions, on unstimulated human PBMCs, as a model system for a resting immune system, and also on acute myeloid leukemia (AML) patient samples to evaluate anti-VISTA antibody effects on primary tumor material. The functions of three anti-human VISTA antibodies were determined by their IgG isotype backbones. An MLR of healthy donor PBMCs was effectively augmented by anti-VISTA-IgG4-Pro and anti-VISTA-IgG1-WT antibodies, as indicated by increased levels of cytokines, T cell activation markers and T cell proliferation. However, in a culture of unstimulated PBMCs of single healthy donors, only anti-VISTA-IgG1-WT antibodies increased the activation marker HLA-DR on resting myeloid cells, and chemokine levels. Interestingly, interactions with different Fc-receptors were required for these effects, namely CD64 for augmentation of MLR, and CD16 for activation of resting myeloid cells. Furthermore, anti-VISTA-IgG1-KO antibodies had nearly no impact in any model system. Similarly, in AML patient samples, anti-VISTA-antibody on IgG4-Pro backbone, but not on IgG1-KO backbone, increased interactions, as a novel readout of activity, between immune cells and CD34+ AML cancer cells. In conclusion, the immune stimulatory effects of antagonistic anti-VISTA antibodies are defined by the antibody isotype and interaction with different Fc-gamma-receptors, highlighting the importance of understanding these interactions when designing immune stimulatory antibody therapeutics for immuno-oncology applications.<\/jats:p>","DOI":"10.3389\/fimmu.2022.862757","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T10:24:16Z","timestamp":1659003856000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Distinct immune stimulatory effects of anti-human VISTA antibodies are determined by Fc-receptor interaction"],"prefix":"10.3389","volume":"13","author":[{"given":"Sven","family":"Mostb\u00f6ck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen Haixia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Fenn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Riegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Strahlhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yining","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gale","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Kroe-Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I\u00f1igo","family":"Tirapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne B.","family":"Vogt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2020.12.008","article-title":"VISTA: A mediator of quiescence and a promising target in cancer immunotherapy","volume":"42","author":"Yuan","year":"2021","journal-title":"Trends Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1674-5","article-title":"VISTA is an acidic pH-selective ligand for PSGL-1","volume":"574","author":"Johnston","year":"2019","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1038\/s41467-020-17756-7","article-title":"T-Cells produce acidic niches in lymph nodes to suppress their own effector functions","volume":"11","author":"Wu","year":"2020","journal-title":"Nat Commun"},{"key":"B4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/imm.13001","article-title":"VSIG-3 as a ligand of VISTA inhibits human T-cell function","volume":"156","author":"Wang","year":"2019","journal-title":"Immunology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jbiotec.2017.08.023","article-title":"Construction of a versatile expression library for all human single-pass transmembrane proteins for receptor pairings by high throughput screening","volume":"260","author":"Yang","year":"2017","journal-title":"J Biotechnol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"15171","DOI":"10.1038\/s41598-020-71519-4","article-title":"An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA","volume":"10","author":"Mehta","year":"2020","journal-title":"Sci Rep"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1261669","DOI":"10.1126\/science.1261669","article-title":"Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53","volume":"349","author":"Yoon","year":"2015","journal-title":"Science"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.580557","article-title":"Ligand-receptor interactions of galectin-9 and VISTA suppress human T lymphocyte cytotoxic activity","volume":"11","author":"Yasinska","year":"2020","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201601","article-title":"VISTA is an activating receptor in human monocytes","volume":"218","author":"Rogers","year":"2021","journal-title":"J Exp Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.077156","article-title":"Differentiation of embryonic stem cells 1 (Dies1) is a component of bone morphogenetic protein 4 (BMP4) signaling pathway required for proper differentiation of mouse embryonic stem cells","volume":"285","author":"Aloia","year":"2010","journal-title":"J Biol Chem"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10637-022-01244-4","article-title":"A small molecule inhibitor of VSIG-8 prevents its binding to VISTA","author":"Chen","year":"2022","journal-title":"Invest New Drug"},{"key":"B12","doi-asserted-by":"crossref","first-page":"eaay0524","DOI":"10.1126\/science.aay0524","article-title":"VISTA is a checkpoint regulator for na\u00efve T cell quiescence and peripheral tolerance","volume":"367","author":"ElTanbouly","year":"2020","journal-title":"Science"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1100660","article-title":"Cutting edge: A monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-Host disease in mouse models","volume":"187","author":"Flies","year":"2011","journal-title":"J Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"eaax1159","DOI":"10.1126\/scitranslmed.aax1159","article-title":"PD-1H (VISTA)\u2013mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus","volume":"11","author":"Han","year":"2019","journal-title":"Sci Transl Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI74589","article-title":"Coinhibitory receptor PD-1H preferentially suppresses CD4+ T cell\u2013mediated immunity","volume":"124","author":"Flies","year":"2014","journal-title":"J Clin Invest"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100619","article-title":"VISTA, a novel mouse ig superfamily ligand that negatively regulates T cell responses","volume":"208","author":"Wang","year":"2011","journal-title":"J Exp Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/intimm\/dxx070","article-title":"The immune checkpoint molecule VISTA regulates allergen-specific Th2-mediated immune responses","volume":"30","author":"Ohno","year":"2018","journal-title":"Int Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1177\/0961203317716322","article-title":"Blocking the VISTA pathway enhances disease progression in (NZB \u00d7 NZW) F1 female mice","volume":"27","author":"Sergent","year":"2018","journal-title":"Lupus"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0109103","article-title":"Characterization of programmed death-1 homologue-1 (PD-1H) expression and function in normal and HIV infected individuals","volume":"9","author":"Bharaj","year":"2014","journal-title":"PLoS One"},{"key":"B20","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s13075-017-1474-y","article-title":"VISTA deficiency attenuates antibody-induced arthritis and alters macrophage gene expression in response to simulated immune complexes","volume":"19","author":"Ceeraz","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"102501","DOI":"10.1016\/j.jaut.2020.102501","article-title":"VISTA deficiency protects from immune complex-mediated glomerulonephritis by inhibiting neutrophil activation","volume":"113","author":"Tham","year":"2020","journal-title":"J Autoimmun"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02641","article-title":"Defining the signature of VISTA on myeloid cell chemokine responsiveness","volume":"10","author":"Broughton","year":"2019","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1158\/1538-7445.AM2017-2996","article-title":"Immune checkpoint protein VISTA suppresses toll-like receptor signaling and the production of inflammatory cytokines [abstract]","volume":"77","author":"Xu","year":"2017","journal-title":"Cancer Res"},{"key":"B24","article-title":"VISTA is a checkpoint regulator for myeloid cells [abstract]","volume":"143","author":"Lines","year":"2014","journal-title":"Immunology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0489","article-title":"Immune-checkpoint protein VISTA regulates antitumor immunity by controlling myeloid cell\u2013mediated inflammation and immunosuppression","volume":"7","author":"Xu","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.595950","article-title":"VISTA: A target to manage the innate cytokine storm","volume":"11","author":"ElTanbouly","year":"2021","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-019-0642-z","article-title":"Analysis of VISTA expression and function in renal cell carcinoma highlights VISTA as a potential target for immunotherapy","volume":"10","author":"Hong","year":"2019","journal-title":"Protein Cell"},{"key":"B28","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.oraloncology.2016.04.005","article-title":"Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma","volume":"57","author":"Kondo","year":"2016","journal-title":"Oral Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-1506","article-title":"VISTA regulates the development of protective antitumor immunity","volume":"74","author":"Mercier","year":"2014","journal-title":"Cancer Res"},{"key":"B30","article-title":"Investigation of PD-1H in DEN-induced mouse liver cancer model","volume":"22","author":"Lei","year":"2018","journal-title":"Eur Rev Med Pharmaco Sci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0313-5","article-title":"VISTA expressed in tumour cells regulates T cell function","volume":"120","author":"Mulati","year":"2019","journal-title":"Brit J Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1830524","DOI":"10.1080\/2162402X.2020.1830524","article-title":"Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade","volume":"9","author":"Pilones","year":"2020","journal-title":"Oncoimmunology"},{"key":"B33","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003382","article-title":"Rationally targeted anti-VISTA antibody that blockades the c-c\u2019 loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an fc independent manner","volume":"10","author":"Thakkar","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.851191","article-title":"Establishment of an ex vivo tissue culture model for evaluation of antitumor efficacy in clear cell renal cell carcinoma","volume":"12","author":"Hong","year":"2022","journal-title":"Front Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2017.89","article-title":"Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients","volume":"30","author":"Kakavand","year":"2017","journal-title":"Modern Pathol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4308","article-title":"VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer","volume":"23","author":"Gao","year":"2017","journal-title":"Nat Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.600973","article-title":"The S228P mutation prevents in vivo and in vitro IgG4 fab-arm exchange as demonstrated using a combination of novel quantitative immunoassays and physiological matrix preparation","volume":"290","author":"Silva","year":"2015","journal-title":"J Biol Chem"},{"key":"B38","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/jssc.201301007","article-title":"Modeling of salt and pH gradient elution in ion-exchange chromatography","volume":"37","author":"Schmidt","year":"2014","journal-title":"J Sep Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1042\/bst026s249","article-title":"Affinity purification of human IgG using immobilised, mutated immunoglobulin-binding domains from protein a of staphylococcus aureus","volume":"26","author":"Brown","year":"1998","journal-title":"Biochem Soc Trans"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1032491","article-title":"Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody","volume":"7","author":"Singh","year":"2015","journal-title":"Mabs"},{"key":"B41","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1016\/j.celrep.2019.07.073","article-title":"Structure and functional binding epitope of V-domain ig suppressor of T cell activation","volume":"28","author":"Mehta","year":"2019","journal-title":"Cell Rep"},{"key":"B42","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.164.10.5313","article-title":"The IgG fc contains distinct fc receptor (FcR) binding sites: The leukocyte receptors Fc\u03b3RI and Fc\u03b3RIIa bind to a region in the fc distinct from that recognized by neonatal FcR and protein a","volume":"164","author":"Wines","year":"2000","journal-title":"J Immunol"},{"key":"B43","doi-asserted-by":"crossref","DOI":"10.1038\/nchembio.2360","article-title":"Global survey of the immunomodulatory potential of common drugs","volume":"13","author":"Vladimer","year":"2017","journal-title":"Nat Chem Biol"},{"key":"B44","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(17)30208-9","article-title":"Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study","volume":"4","author":"Snijder","year":"2017","journal-title":"Lancet Haematol"},{"key":"B45","doi-asserted-by":"crossref","DOI":"10.1158\/2326-6066.CIR-14-0161","article-title":"The immunological synapse","volume":"2","author":"Dustin","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1420370112","article-title":"Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses","volume":"112","author":"Liu","year":"2015","journal-title":"Proc Natl Acad Sci"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00292","article-title":"Fc\u03b3R-binding is an important functional attribute for immune checkpoint antibodies in cancer immunotherapy","volume":"10","author":"Chen","year":"2019","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.ccell.2018.05.005","article-title":"Selective Fc\u03b3R Co-engagement on APCs modulates the activity of therapeutic antibodies targeting T cell antigens","volume":"33","author":"Waight","year":"2018","journal-title":"Cancer Cell"},{"key":"B49","unstructured":"CI-8993: First-in-Class antagonist of VISTA [Internet]2021"},{"key":"B50","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1136\/jitc-2020-SITC2020.0392","article-title":"Phase 1 study of CI-8993 anti-VISTA antibody in patients with advanced solid tumor malignancies","volume":"8","author":"Martinez","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1158\/1538-7445.AM2021-1637","article-title":"Abstract 1637: A fully human anti-vista antibody as a promising therapy against poorly immunogenic tumors","volume":"81","author":"Guillaudeux","year":"2021","journal-title":"Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-380121","article-title":"Properties of mouse and human IgG receptors and their contribution to disease models","volume":"119","author":"Bruhns","year":"2012","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.862757\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T10:24:33Z","timestamp":1659003873000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.862757\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,28]]},"references-count":52,"alternative-id":["10.3389\/fimmu.2022.862757"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.862757","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,28]]},"article-number":"862757"}}